Sedana Medical: Updated FDA timeline and Q2 preview - Redeye
Redeye lowers its fair value range following the updated FDA timeline, which will likely hold
the share back from any sustainable positive momentum for some time. Moreover, we
provide our Q2 2023 preview for the report due on July 21.
ANNONS
Redeye lowers its fair value range following the updated FDA timeline, which will likely hold
the share back from any sustainable positive momentum for some time. Moreover, we
provide our Q2 2023 preview for the report due on July 21.